Purpose: Prostate-specific antigen (PSA) doubling-time (PSA-DT) is an important indicator of progression and survival in men with prostate cancer. Three major limitations regarding PSA-DT determination may lead to inconsistent results: the variety of mathematical methods currently applied, the non-standardized handling of input variables and the potential lack of accuracy due to PSA variability. The aim of this project was to develop a reproducible PSA-DT determination tool which simultaneously provides a PSA-DT error estimation.
Materials And Methods: An internet-based PSA-DT calculation tool via nonlinear optimization implementing the least squares error method using the most recent three PSA values was developed. PSA-DT calculation error is estimated via randomly disturbed measurement data streams (n=65) based on a variable (5-25%) PSA variability.
Results: According to a simulation in five men, PSA-DT was calculated to be between 1.7 and 15 month (mean: 6.3 month) and determined with another standard tool between 1.3 and 14.5 month (mean: 4.2 month).
Conclusion: We present a defined, open and reproducible PSA-DT calculation and PSA-DT error estimation tool based on a standardized PSA data input. This tool is not better compared to other methods but is scientifically standardized and freely accessible via the following internet address: http://adam.drahtwarenhandlung.at/webapp/mg2008/chapter_prostata4/example_psa.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
European Association of Urology biochemical recurrence risk groups after radical prostatectomy: External validation and identification of independent risk factors for progression and death.
Actas Urol Esp (Engl Ed)
September 2023
Urology Department, Hospital Universitario 12 de Octubre, Spain.
Background: The EAU proposed a progression and death risk classification in patients with biochemical recurrence after radical prostatectomy (PR).
Objective: To validate the EAU BCR-risk classification in our setting and to find factors related to progression and death.
Material And Methods: Multicenter, retrospective, observational study including 2140 patients underwent RP between 2011 and 2015.
PSMA-11 PET/CT for Detection of Recurrent Prostate Cancer in Patients With Negative Choline PET/CT.
Clin Genitourin Cancer
April 2023
Département de Médecine Nucléaire, Centre Hospitalier Universitaire de Brest, Brest, France; Inserm, Univ Brest, CHU Brest, UMR 1304, GETBO, Brest, France. Electronic address:
Article Synopsis
- Prostate adenocarcinoma is the most common cancer among men, and a significant number of patients face biochemical recurrence (BR) after treatment, making early detection of recurrence critical for personalized therapy.
- This study evaluated the effectiveness of Ga-PSMA-11 PET/CT scans in identifying recurrence in prostate cancer patients who had negative results from another type of scan (F-choline PET/CT) and examined its detection rates based on various PSA levels.
- Results showed a 65.9% overall detection rate for Ga-PSMA-11 PET/CT, with 75.9% of patients starting treatment based on positive scan results, indicating its potential to influence management decisions significantly.
Integrating Prostate-specific Antigen Kinetics into Contemporary Predictive Nomograms of Salvage Radiotherapy After Radical Prostatectomy.
Eur Urol Oncol
June 2022
Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA. Electronic address:
Background: Salvage radiotherapy (SRT) is an established treatment for men with biochemical recurrence following radical prostatectomy (RP). There are several risk factors associated with adverse outcomes; however, the value of postoperative prostate-specific antigen (PSA) kinetics is less clear in the ultrasensitive PSA era.
Objective: To characterize the impact of PSA kinetics on outcomes following SRT and generate nomograms to aid in identifying patients with an increased risk of adverse clinical outcomes.
[Prediction of life expectancy for prostate cancer patients based on the kinetic theory of aging of living systems].
Adv Gerontol
July 2018
Central Children's Clinical Hospital, Russian Federal Medical and Biological Agency, 20, Moskvorech'e str., Moscow, 115309, Russian Federation;
The article presents a methodical approach for prediction of life expectancy for people diagnosed with prostate cancer based on the kinetic theory of aging of living systems. The life expectancy is calculated by solving the differential equation for the rate of aging for three different stage of life - «normal» life, life with prostate cancer and life after combination therapy for prostate cancer. The mathematical model of aging for each stage of life has its own parameters identified by the statistical analysis of healthcare data from the Zharinov's databank and Rosstat CDR NES databank.
View Article and Find Full Text PDFAn examination of the dynamic changes in prostate-specific antigen occurring in a population-based cohort of men over time.
BJU Int
August 2012
Division of Urology, Duke University Medical Center, Durham, NC 27710, USA.
Objective: • To determine whether prostate-specific antigen velocity (PSA-V), PSA doubling time (PSA-DT), or PSA percentage change (PSA-PC) add incremental information to PSA alone for community-based men undergoing prostate cancer (PCa) screening.
Participants And Methods: • A population-based cohort of 11 872 men from Olmsted County, MN undergoing PSA screening for PCa from 1993 to 2005 was analysed for PSA, PSA-DT, PSA-PC and PSA-V and subsequent PCa. • Receiver-operating characteristics curves and logistic regression were used to calculate the area under the curve (AUC) and Aikaike's information criterion.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!